Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17074780 | 1.00 | — | — | |
| SCHEMBL687260 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL18726122 | 0.82 | TDP1 (0.52) | — | |
| SCHEMBL1579734 | 0.79 | — | — | |
| Nitric Acid SCHEMBL29142706 | 0.78 | POLB (0.38) | — | |
| SCHEMBL19480310 | 0.77 | — | — | |
| SCHEMBL24553869 | 0.76 | PRMT3 (0.35) | — | |
| SCHEMBL15426781 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL3855671 | 0.71 | PRMT3 (0.93) | — | |
| Hydrochloric Acid SCHEMBL3610130 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010905-A | Pyrazolyl derivatives as anticancer agents | 诺华股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4344702-B1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2026-01-28 | — | — | EP | disclosed |
| EP-4344702-A2 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | Novartis AG (CH) | 2024-04-03 | — | — | EP | disclosed |
| EP-4076662-B1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2024-01-31 | — | — | EP | disclosed |
| US-20240002925-A1 | METHODS, SYSTEMS AND KITS FOR POLYPEPTIDE PROCESSING AND ANALYSIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-01-04 | — | — | US | disclosed |
| US-20230381319-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-11-30 | — | — | US | disclosed |
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | NOVARTIS AG (CH) | 2023-07-18 | — | — | US | disclosed |
| US-20230192700-A1 | PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12 | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-22 | — | — | US | disclosed |
| WO-2023091961-A2 | METHODS AND SYSTEMS FOR AUTOMATED SAMPLE PROCESSING | ERISYON INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| CN-115916799-A | Methods, systems, and kits for polypeptide processing and analysis | 德克萨斯大学系统董事会 | 2023-04-04 | — | — | CN | disclosed |
| US-20120027796-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110311583-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| CN-102281899-A | Novel lipids and compositions for delivery of therapeutic agents | — | 2011-12-14 | — | — | CN | disclosed |
| EP-2367571-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Alnylam Pharmaceuticals Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2011110859-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISEASES SUCH AS COPD | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2011-09-15 | — | — | WO | disclosed |
| EP-2355658-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Alnylam Pharmaceuticals Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20110183979-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-28 | — | — | US | disclosed |
| WO-2011089132-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-28 | — | — | WO | disclosed |
| WO-2010054406-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054405-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |